lipodystrophy raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-10. Anything still debated is marked as such rather than presented as settled.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Modern-day diabetes is associated with two terms in the Chinese language. The traditional term, xiāo kě (消渴), means "wasting-thirst" and correlates closely with diabetes in most instances of historical description. The more modern term, táng niǎo bìng (糖尿病), means "sugar urine disease", and is equivalent to diabetes mellitus. It has been suggested that the modern term is derived from exchanges with Ayurvedic practitioners who called the condition madhumeha ("honey urine"). Within the Sinosphere (regions of East and Southeast Asia historically influenced by the linguistic and literary traditions of the Chinese empire), this etymology has also been borrowed into Korean (tang nyo byeong [당뇨병]) and Japanese (tou nyou byou [とうにょうびょう]). Reviews of diabetology history in Traditional Chinese medicine have classified the diagnosis and treatment of xiāo kě (消渴) into four periods, summarized below. Classic texts provided a typology of the condition and outlined various recommendations on diagnosis, development, treatment, and prevention. Knowledge of wasting-thirst was integrated with knowledge of diabetes during the Qing dynasty.
Some studies report increased depressive symptoms and anxiety, potentially linked to the sensitization of the hypothalamic-pituitary-adrenal (HPA) axis and elevated cortisol levels. Others find no association or even reduced symptoms. Copper IUDs confer an increased risk of longer, heavier, and/or more painful menstrual periods.
=== Opposition to COVID-19 vaccine requirements (2021) === In October 2021, the In-N-Out location in San Francisco was ordered closed by the San Francisco Department of Public Health (SFDPH), for failure to enforce the public health order requiring that all dine-in patrons of restaurants present proof that they are fully vaccinated for COVID-19. The location had posted signage warning of the mandate, but the SFDPH received complaints that it was not actually enforced. The company's chief legal officer Arnie Wensinger stated that the company "fiercely disagree[s] with any government dictate that forces a private company to discriminate against customers who choose to patronize their business". The location was allowed to re-open for takeout service only until it demonstrates "an adequate process and procedure for complying with the health order". Later that month, after an In-N-Out location in Contra Costa County was similarly ordered closed by public health for not complying with its vaccine mandate, all In-N-Out locations in the region closed their dining rooms and began operating with takeout service only. The locations attracted anti-mandate demonstrations in support of the company.
Sources: en.wikipedia.org
=== Mechanism of action === Elexacaftor/tezacaftor/ivacaftor is a tridrug treatment in which the medications work together to increase the transport of chloride and sodium ions and correct fluid shifts that are dysregulated in cystic fibrosis. Its effectiveness is dependent on the type of CF mutations the patient has.
General Public were an English new wave band, formed in Birmingham in 1983, by vocalists Dave Wakeling and Ranking Roger of the Beat, and which also included former members of Dexys Midnight Runners, the Specials, and the Clash. They are best remembered for their hits "Tenderness" (1984) and "I'll Take You There" (1994).
=== Imaging procedure === Since 68Ga is a positron emitter, 68Ga-Trivehexin is applicable for PET imaging. However, PET is rarely used as a standalone imaging technique these days. Most clinics use PET/CT or even PET/MRI systems that acquire morphological and functional images in a single workflow and thus, provide more detailed and useful medical information to the physician. For clinical PET/CT diagnostics, an activity in the range of 80–150 MBq 68Ga-Trivehexin is injected intravenously (i.v.). The tracer then distributes with the blood flow and moves into tissues by diffusion, where it specifically binds to its target αvβ6-integrin, while an excess is excreted via the kidneys and the urine. As a result, 68Ga-Trivehexin and, therefore, the positron-emitting radionuclide 68Ga, is preferably accumulated by αvβ6-integrin abundant tissues (for example, tumor tissue). Next, a PET/CT scanner is used to detect the gamma radiation which is generated by the annihilation of the positrons emitted by 68Ga (not the actual positrons, which do not leave the body but travel only a few millimetres through the tissue). The spatial distribution of the annihilation events is reconstructed from the raw detector data (referred to as listmode data), which eventually delivers a 3-dimensional data set of radioactivity distribution in the body. These data allow the visualization of αvβ6-integrin positive tissues as 2-dimensional tomographic images or 3-dimensional volume rendering. Typically, the PET/CT imaging is performed 45–60 minutes after the i.v. administration of 68Ga-Trivehexin.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.